NCT03746652Unknown2 期
A Phase 2, Multicenter, Open-label, Single-Arm Study to Evaluate the Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone as Second Line Therapy in Multiple Myeloma Patients Who Have Received Prior Treatment With a Lenalidomide Based Regimen
Hellenic Society of Hematology1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2018年12月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Overall Response Rate (ORR)
研究概览
简要总结
This study will assess the efficacy of daratumumab in combination with ixazomib and dexamethasone as second line treatment for relapsed Multiple Myeloma patients.
详细描述
This is a Phase 2, single-arm study of daratumumab in combination with ixazomib and dexamethasone as second line treatment for relapsed Multiple Myeloma patients initially treated with lenalidomide-based regimens. Daratumumab is a human IgG1ĸ monoclonal antibody that binds with high affinity to a unique epitope on CD38, a transmembrane glycoprotein. It is a targeted immunotherapy that attacks tumor cells that overexpress CD38, in a variety of hematological malignancies including multiple myeloma. Ixazomib is an orally administered proteasome inhibitor with anti-myeloma activity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females at least 18 years of age.
- •Voluntary written informed consent before performance of any study-related procedure.
- •Relapsed patients with measurable disease parameters according to the IMWG:
- •IgG multiple myeloma: Serum M-protein level ≥1.0 g/dL or urine M-protein level ≥200 mg/24 hours, or
- •IgA, IgD, IgE, IgM multiple myeloma: Serum M-protein level ≥0.5 g/dL or urine M-protein level ≥200 mg/24 hours; or
- •Light chain multiple myeloma, for patients without measurable disease in the serum or urine: Serum immunoglobulin FLC ≥10 mg/dL and abnormal serum immunoglobulin kappa lambda FLC ratio.
- •Patients who have received one prior regimen for MM based on lenalidomide (induction followed by any planned high dose therapy or consolidation or maintenance would be considered as one regimen).
- •Patients must have documented evidence of PD based on the investigator's determination of response as defined by the modified IMWG criteria.
- •Willingness and ability to participate in study procedures.
- •Patient has a Karnofsky Performance Status ≥
- •For patients experiencing toxicities resulting from previous therapy, the toxicities must be resolved or stabilized to ≤ Grade
- •Patients with adequate bone marrow reserve, as evidenced by:
- •Absolute neutrophil count (ANC) ≥ 1.0×10^9/L.
- •Platelet count ≥ 75×10^9/L for patients in whom < 50% of bone marrow nucleated cells are plasma cells and ≥ 50×10^9/L for patients in whom ≥ 50% of bone marrow nucleated cells are plasma cells (transfusions are not permitted to reach this level).
- •All of the following results during Screening:
- •Hemoglobin level ≥8 g/dL (≥ 4.65 mmol/L) (transfusions are not permitted to reach this level).
- •Creatinine clearance ≥30 mL/min by CKD-EPI.
- •Alanine aminotransferase (ALT) level ≤ 2.5 times the upper limit of normal (ULN).
- •Aspartate aminotransferase (AST) level ≤ 2.5×ULN.
- •Total bilirubin level ≤ 1.5×ULN, (except for Gilbert Syndrome: direct bilirubin ≤1.5×ULN).
- •Serum calcium corrected for albumin ≤ 14.0 mg/dL (≤ 3.5 mmol/L), or free ionized calcium ≤ 6.5 mg/dL (≤ 1.6 mmol/L).
排除标准
- •Previous exposure to anti-CD38 antibodies or ixazomib.
- •Systemic treatment with or strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of St. John's wort within 14 days before C1D
- •Patient has received anti-myeloma treatment within 2 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is longer, prior to C1D
- •The only exception is emergency use of a short course of corticosteroids (equivalent of dexamethasone 40 mg/day for a maximum of 4 days) for palliative treatment before C1D
- •Previous allogenic stem cell transplant; or autologous stem cell transplantation (ASCT) within 12 weeks before C1D
- •Patient has received radiotherapy within 14 days of C1D
- •Urgent localized radiotherapy for Spinal Cord Compression is allowed.
- •History of malignancy (other than MM) within 3 years before C1D1 (exceptions are squamous and basal cell carcinomas of the skin, carcinoma in situ of the cervix or breast, or other noninvasive lesion that in the opinion of the investigator, with concurrence with the Sponsor's medical monitor, is considered cured with minimal risk of recurrence within 3 years).
- •Clinical signs of meningeal involvement of MM.
- •Patient has clinically significant cardiac disease, including: unstable angina or myocardial infarction within 6 months to C1D1, NYHA Class III or IV heart failure, uncontrolled angina, history of severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or Grade 3 conduction system abnormalities unless patient has a pacemaker, or ECG showing a baseline QT interval as corrected by Fridericia's formula (QTcF) > 470 msec.
- •Known active hepatitis A, B, or C.
- •Known HIV infection.
- •Patient has a history of significant neurological, endocrine, gastrointestinal, respiratory, or inflammatory illness or stroke; or COPD requiring > 2 hospitalizations in the preceding 12 months from C1D
- •Patient has plasma cell leukemia (> 2.0×10^9/L circulating plasma cells by standard differential) or Waldenström's macroglobulinemia or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) or amyloidosis.
- •Patient has uncontrolled hypertension or hypertension requiring >2 medications for adequate control within 14 days to C1D
- •Patient has uncontrolled diabetes within 14 days to C1D1 or diabetes mellitus with > 2 episodes of ketoacidosis in the preceding 12 months from C1D
- •Patient has ongoing ≥ Grade 2 peripheral neuropathy.
- •Patient had ≥ Grade 3 rash during prior therapy.
- •Patient has had major surgery within 14 days prior to C1D1, or has not fully recovered from an earlier surgery, or has surgery planned during the time the patient is expected to participate in the study or within 2 weeks after the last dose of study drug administration. Note: patients with planned surgical procedures to be conducted under local anesthesia may participate. Kyphoplasty or vertebroplasty are not considered major surgery.
- •Pregnant or nursing women.
- •Any other clinically significant medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence.
- •Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial.
- •Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment.
- •Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.
- •Known GI disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing.
研究组 & 干预措施
DId
Experimental
Daratumumab, Ixazomib, Dexamethasone
干预措施: Daratumumab, Ixazomib, Dexamethasone (Drug)
结局指标
主要结局
Overall Response Rate (ORR)
时间窗: From first day of treatment until end of study, documented progressive disease (PD), or death (approximately up to 36 months)
ORR is defined as the proportion of patients who achieve a best response of PR or better, using modified IMWG criteria.
次要结局
- Duration of response (DOR)(From the date of initial documentation of a response (CR, VGPR or PR) to the date of first documented evidence of PD, as defined in the IMWG criteria (approximately up to 36 months))
- Progression-free survival (PFS)(From C1D1 to either PD, according to the IMWG criteria, or death, whichever occurs first (approximately up to 36 months))
- Serum bone markers(The evaluation will be performed on C1D1 and then every 3 months until PD (approximately up to 36 months))
- Evaluation of the hematologic and non-hematologic toxicity profile of the combination.(From first day of treatment until end of study, PD, or death (approximately up to 36 months))
- Time to next therapy (TNT)(From C1D1 to the date of the next anti-neoplastic therapy or death from any cause, whichever comes first (approximately up to 36 months))
- Minimal Residual Disease (MRD) negativity using Next-Generation Flow Cytometry (NGFC)(Assessed every 3 months post CR/sCR until PD (approximately up to 36 months))
- Time to disease progression (TTP)(From C1D1 to the date of first documented evidence of PD, as defined in the IMWG criteria (approximately up to 36 months))
- Overall survival (OS)(From C1D1 to the date of death from any cause (approximately up to 36 months))
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With DaratumumabRecurrent Plasma Cell MyelomaRefractory Plasma Cell MyelomaNCT04407442University of California, San Francisco5
招募中
2 期
Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous TherapyAL AmyloidosisNCT05066607Intergroupe Francophone du Myelome46
Unknown
4 期
Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received LenalidomideMultiple MyelomaNCT04989140Peking Union Medical College Hospital60
进行中（未招募）
2 期
Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaPlasma Cell MyelomaNCT03942224Emory University49
已完成
1 期
Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot StudyHigh Risk Smoldering Multiple MyelomaMultiple MyelomaNCT02697383Memorial Sloan Kettering Cancer Center14